Citius Pharmaceuticals Inc vs Synchrony Financial — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M), while Synchrony Financial trades at $78.37 (market cap $25.53B). The key difference: Synchrony Financial is far larger — about 1275.9× Citius Pharmaceuticals Inc's market cap, and Synchrony Financial pays a 1.73% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | SYF | |
|---|---|---|
Market Cap | $20.01M | $25.53B |
Sector | Health | Financials |
52-Week High | $1.82 | $88.47 |
52-Week Low | $0.48 | $63.78 |
Enterprise Value | $16.23M | — |
Dividend Yield | — | 1.73% |
Trailing returns across standard periods
Latest headlines on both assets
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →